Interestingly, neuropsychiatric outcomes (i.e., depression, fatigue) did not appear to be substantially different in NMDAR1-abs seropositive compared to seronegative patients at either follow-up timepoint, which is in contrast to previous study results [12, 52]. This evidence concerns the gene GRIN1 and depressive symptom measurement.